Tuesday, July 16, 2019
Mindshare Medical today announced that its RevealAI-Lung product has received sales authorization in Europe (CE mark) for use with lung TAC.
The product, a computer-aided diagnostic software (CADx) for the diagnosis of lung cancer, is the first diagnostic platform of its kind to obtain regulatory authorization. RevealAI-Lung can significantly improve the diagnostic effectiveness of physicians and optimize follow-up recommendations, while integrating seamlessly with existing image and communication archiving (PACS) systems.
Mindshare has shown potential to reduce false positives and the time needed to have a diagnosis, which can reduce patients' exposure to imaging procedures and unnecessary biopsies in some cases, while providing the opportunity to treat cancer of lung in an initial phase.
Lung cancer is the leading cause of death among women and men around the world with 376,000 deaths in Europe in 2017, accounting for 20% of all cancer deaths. In addition, it represents the loss of 3.2 million years of life adjusted for disability per year.
Considering the 5-year European net survival rate of 18%, the ability to intercept and treat a malignant nodule even just a few months earlier could offer enormous benefits to patients. In addition to these clinical advantages, when considering the economic burden for the health system, reducing the unnecessary procedures of false positives is a considerable saving. RevealAI from Mindshare can play a vital role in the adoption of valuable healthcare and increase the implementation of lung cancer screening programs throughout Europe.
"At Mindshare, we are pleased to present RevealAI to the European market as the first authorized CADx product, and our partners in the United Kingdom and the continent have recognized the value that Mindshare can bring to the treatment of pulmonary nodules, from radiology to surgery. Thoracic, there are numerous implications and we are excited to offer this benefit to help patients and help the health system to provide medical care. " Dr. Michael Calhoun . CEO of Mindshare Medical
Mindshare Medical develops revolutionary technologies that support clinical decisions based on tests and that provide personalized diagnosis and counseling to offer more effective follow-up procedures and treatments. This approach of radiology of precision is designed to drastically optimize the results and reduce the economic burden of health organizations. Mindshare solutions are designed to conform to existing clinical workflows, which puts a source of revolutionary information within reach of physicians.
